Highlights

  • Tissue Repair opened an equal-access off-market share buy-back for eligible shareholders.
  • The buy-back allows the company to repurchase up to A$1 million of ordinary shares.
  • The Offer Price is A$0.13 per share and closes on 27 October 2026.
  • The buy-back forms part of arrangements associated with the company’s planned ASX removal.
  • Shareholders who participate will receive payment after completion of the buy-back process.

Tissue Repair Ltd (ASX:TRP) is a biotechnology company that has been listed on the Australian Securities Exchange. The company’s latest announcement relates to an off-market equal-access share buy-back and associated steps connected with its planned removal from the ASX official list.

Buy-Back Offer Details

Tissue Repair announced the opening of an off-market equal-access share buy-back after issuing its buy-back booklet to shareholders. The company intends to repurchase up to 7,692,307 ordinary shares at A$0.13 per share, representing a maximum total consideration of A$1 million.

The company stated that the buy-back represents approximately 12% to 13% of issued ordinary capital. Eligible shareholders can choose whether to participate, subject to the terms and conditions outlined in the offer booklet.

Shareholder Approvals and Delisting Process

Tissue Repair shareholders previously voted on resolutions relating to the company’s proposed delisting and buy-back arrangements. The company reported Shareholder approval for both resolutions.

The buy-back forms part of the broader process for the company’s removal from the ASX official list. Following delisting, shares would no longer trade on the ASX and holders would need to consider alternative arrangements for any remaining holdings.

Offer Timetable

The buy-back opened on 29 September 2026 and is scheduled to close at 5:00pm AEDT on 27 October 2026. The company expects the buy-back date to occur on 29 October 2026, with payment scheduled for 30 October 2026.

Eligible shareholders may choose to sell all or part of their holdings under the offer, or decline to participate. If total acceptances exceed the available buy-back limit, applications will be scaled back proportionately.

Financial Impact

Tissue Repair reported cash of approximately A$5.46 million as at 31 August 2026. The company stated that if the full A$1 million buy-back amount is utilised, cash would reduce by the corresponding amount before considering other costs.

The company provided pro forma financial information showing the expected impact of the buy-back assuming full participation. These figures are based on the assumptions outlined in the offer booklet.

Considerations for Shareholders

The buy-back provides eligible shareholders with the option to participate before the planned ASX delisting process progresses. Shareholders who retain shares after delisting would no longer have access to ASX trading facilities.

The company noted that participation is voluntary and that the final outcome depends on shareholder decisions and the level of applications received under the offer.

Key Insights

Tissue Repair’s latest update focuses on the mechanics of its off-market buy-back and planned ASX delisting process. The announcement outlines the offer structure, timetable and financial implications, while shareholders determine their participation based on the terms provided in the offer documents.